Antipsychotic switching in bipolar disorders: a systematic review (Q35020871)

5 August 2017

Antipsychotic switching in bipolar disorders: a systematic review (English)

1 reference

5 August 2017

1 reference

Iria Grande

1

0 references

Miguel Bernardo

object named as

Miquel Bernardo

2

0 references

Eduard Vieta

object named as

Eduard Vieta

6

0 references

Julio Bobes

3

object named as

Julio Bobes

1 reference

5 August 2017

Jerónimo Saiz-Ruiz

4

1 reference

PubMed ID

24139622

5 August 2017

Cecilio Álamo

5

1 reference

5 August 2017

21 October 2013

1 reference

The International Journal of Neuropsychopharmacology

5 August 2017

1 reference

5 August 2017

17

1 reference

5 August 2017

3

1 reference

5 August 2017

497-507

1 reference

Treatment strategies according to clinical features in a naturalistic cohort study of bipolar patients: a principal component analysis of lifetime pharmacological and biophysic treatment options

5 August 2017

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Switching to quetiapine in patients with acute mania who were intolerant to risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

New treatment guidelines for acute bipolar depression: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

What we know and what we don't know about the treatment of schizoaffective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Cognitive neuropsychiatry: conceptual, methodological and philosophical perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Converting from brand-name to generic clozapine: a review of effectiveness and tolerability data

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Atypical antipsychotic tolerability and switching strategies in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

2-Year course of bipolar disorder type I patients in outpatient care: factors associated with remission and functional recovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Changes in outpatient lithium treatment in the Netherlands during 1996-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Clinical factors leading to lamotrigine prescription in bipolar outpatients: subanalysis of the SIN-DEPRES study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Aripiprazole in patients with bipolar mania and beyond: an update of practical guidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Mixed states in DSM-5: implications for clinical care, education, and research

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Head to head comparisons as an alternative to placebo-controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

International consensus group on depression prevention in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Declaración PRISMA: una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

The need for publishing the silent evidence from negative trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

Managing weight gain and metabolic issues in patients treated with atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

7 January 2021

Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

7 January 2021

Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

7 January 2021

Switching outpatients between atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

7 January 2021

Paradoxical motor syndrome following a switch from atypical neuroleptics to aripiprazole

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

7 January 2021

A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

7 January 2021

Quetiapine indication shift in the elderly: diagnosis and dosage in 208 psychogeriatric patients from 2000 to 2006

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

7 January 2021

Switching between clozapine and risperidone treatment

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

7 January 2021

Emerging guidelines for the use of antipsychotic polypharmacy

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

7 January 2021

The use of first generation versus second generation antipsychotics as add-on or as switch treatment and its effect on QTC interval: the Italian experience in a real-world setting

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

7 January 2021

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

7 January 2021

Use of long-acting risperidone in the treatment of bipolar patients

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

7 January 2021

Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

7 January 2021

Performance improvement CME: Long-term treatment of bipolar disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145713001168

7 January 2021

10.1017/S1461145713001168

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

24139622